Treatment of AML (acute myeloid leukemia) in Germany
Intensive therapy protocols and bone marrow transplantation with high remission rates
Acute myeloid leukemia (AML) is an aggressive malignant disease of the hematopoietic system. RheinRegio Klinik Zentrum uses individualized treatment regimens, including induction chemotherapy, targeted drugs and allogeneic transplantation. Our goal is to achieve complete remission with minimal complications.
Symptoms of AML
General manifestations
- Severe weakness and pallor (anemia)
- Frequent infections (neutropenia)
- Bleeding gums, bruising (thrombocytopenia)
- Fever without obvious cause
Specific signs
- Gingivitis (with monoblastic variant)
- Skin infiltrates (leukemides)
- Enlarged liver and spleen
Critical sign: Blast cells in peripheral blood (>20%).
Diagnosis of AML at RheinRegio Klinik Zentrum
<p>At RheinRegio Klinik Zentrum they carry out:</p>
<ul>
<li aria-level=”1″>Cytochemical studies (myeloperoxidase, NASD-chloroacetate)</li>
<li aria-level=”1″>Flow cytometry (CD13, CD33, CD117)</li>
<li aria-level=”1″>Molecular genetic tests:</li>
<ul>
<li aria-level=”2″>NPM1, FLT3, CEBPA mutations</li>
<li aria-level=”2″> Cytogenetic analysis (karyotyping)</li>
</ul>
<li aria-level=”1″>PET-CT (if extramedullary lesions are suspected)</li>
</ul>
<p>Innovation: Monitoring of minimal residual disease (MRD) using the NGS method.</p>
Each direction is supervised by advanced oncologists.
Find out the cost of treatment
To find out the approximate cost of treatment, answer a few questions and we will contact you!
Classification and stages of AML
Types according to WHO 2022
- AML with recurrent genetic abnormalities
- AML associated with myelodysplasia
- Therapy-associated AML
Risk stratification
- Favorable: t(8;21), inv(16)
- Unfavorable: complex karyotype, FLT3-ITD+
Treatment options for AML
1. Induction therapy
- “7+3” (cytarabine + anthracycline) – standard
- CPX-351 (for secondary AML)
2. Consolidation
- High-dose cytarabine (3-4 courses)
- Allogeneic BMT (intermediate/poor risk)
3. Targeted therapy
- FLT3 inhibitors (midostaurin)
- IDH inhibitors (ivosidenib)
Survival prognosis
- <ul>
<li aria-level=”1″>Favorable group: 60-70%</li>
<li aria-level=”1″>Intermediate: 40-50%</li>
<li aria-level=”1″>Unfavorable: 20-30%</li>
</ul>
<p>Conclusion: Our clinic uses personalized strategies for each case of AML.</p>
<p>Sign up for a consultation — we are ready to help in the fight against the disease!</p>
Our clinics
The association of clinics RheinRegio Klinik Zentrum offers the organization of AML treatment in Germany without intermediaries, providing access to the country’s leading oncology clinics. We combine advanced techniques, an individual approach and the highest level of medical care, giving hope even in difficult cases.
Why RheinRegio Klinik Zentrum?
- Transplant center (100+ allogeneic BMT annually)
- Reduced toxicity protocols for the elderly
- Clinical trials (new inhibitors)
- 24/7 support for international patients
